Patents by Inventor Rodrigo R. RUIZ-SOTO

Rodrigo R. RUIZ-SOTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS
    Publication number: 20230190638
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Application
    Filed: July 25, 2022
    Publication date: June 22, 2023
    Inventors: Angela ROMANELLI, Rodrigo R. RUIZ-SOTO, Jose PONTE, Jutta DECKERT, Jan PINKAS
  • Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
    Patent number: 11395796
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: July 26, 2022
    Assignee: Debiopharm International, S.A.
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
    Publication number: 20220168326
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Inventors: Jose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
  • ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
    Publication number: 20220160889
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers. e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: July 21, 2021
    Publication date: May 26, 2022
    Applicants: ImmunoGen, Inc., Merck Sharp & Dohme Corp.
    Inventor: Rodrigo R. RUIZ SOTO
  • Therapeutic combinations comprising anti-FOLR1 immunoconjugates
    Patent number: 11033564
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: June 15, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Jose Ponte, Jan Pinkas, Rodrigo R. Ruiz-Soto
  • THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
    Publication number: 20200397806
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 24, 2020
    Inventors: Jose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
  • ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS
    Publication number: 20190183788
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 20, 2019
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
    Publication number: 20190167704
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 6, 2019
    Inventors: Jose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
  • Therapeutic combinations comprising anti-FOLR1 immunoconjugates
    Patent number: 10172875
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: January 8, 2019
    Assignee: ImmunoGen, inc.
    Inventors: Jose Ponte, Jan Pinkas, Rodrigo R. Ruiz-Soto
  • ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS
    Publication number: 20180333503
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-PD-1 antibodies or antigen-binding fragments thereof (e.g., pembrolizumab) are provided. Methods of administering the combinations to treat cancers, e.g., ovarian, peritoneal, or fallopian tube cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: May 15, 2018
    Publication date: November 22, 2018
    Applicants: ImmunoGen, Inc., Merck Sharp & Dohme Corp.
    Inventor: Rodrigo R. RUIZ SOTO
  • Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates
    Publication number: 20170095571
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Application
    Filed: September 16, 2016
    Publication date: April 6, 2017
    Inventors: Jose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
  • ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS
    Publication number: 20170000900
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 5, 2017
    Inventors: Angela ROMANELLI, Rodrigo R. RUIZ-SOTO, Jose PONTE, Jutta DECKERT, Jan PINKAS